New Jersey Senate Bill S1191

New Jersey 2022-2023 Regular Session

• Introduced: 1/31/22
• Refer: 1/31/22

Caption

Requires health insurers, SHBP, and SEHBP to provide coverage for medication and treatment for hepatitis C.

Impact

The implications of S1191 are significant for public health in New Jersey. By expanding coverage for hepatitis C treatment, the bill aims to increase diagnosis and treatment rates, ultimately contributing to better health outcomes for individuals with the disease. Health insurance plans will be required to align their policies with this act, which serves to protect vulnerable populations and promote equitable access to healthcare resources. The act takes effect 90 days after its enactment, allowing time for health insurers to adjust their policies accordingly.

Summary

Senate Bill S1191 is an important piece of legislation that mandates health insurers, including those under the State Health Benefits Program (SHBP) and School Employees' Health Benefits Program (SEHBP), to provide comprehensive coverage for the medication and treatment of hepatitis C. The bill specifies that coverage cannot be denied based on a person's substance use, the stage of the disease, or whether the prescribing healthcare professional is a specialist. This ensures that all affected individuals have access to necessary treatments without discrimination.

Contention

Despite its positive intent, S1191 has faced scrutiny regarding its potential financial impact on health insurers and the overall healthcare system. Critics argue that mandated coverage could lead to higher premiums for consumers as insurers adjust to the increased costs associated with treating chronic conditions like hepatitis C. There are ongoing discussions about balancing the need for comprehensive coverage with the economic realities of healthcare provision, making this bill a focal point in broader debates about health reform in the state.